期刊文献+

微波消融治疗继发性甲状旁腺功能亢进症的有效性和安全性:Meta分析 被引量:4

Efficacy and safety of microwave ablation for secondary hyperparathyroidism:Meta-analysis
下载PDF
导出
摘要 目的系统评价微波消融(MWA)治疗继发性甲状旁腺功能亢进症(SHPT)的有效性和安全性。方法检索PubMed、Cochrane Library、Embase、中国知网和万方医学网自建库至2020年12月31日发表的MWA治疗SHPT相关文献。采用Stata 15.0软件分析MWA治疗SHPT的有效性和安全性。结果依据纳入及排除标准,最终纳入9篇文献、共249例SHPT患者。与消融前相比,MWA后1天[加权均数差(WMD)=1142.04,95%CI(783.03,1501.06),P<0.001]、1周[WMD=859.85,95%CI(758.97,960.74),P<0.001]、1个月[WMD=800.29,95%CI(687.12,913.47),P<0.001]和6个月[WMD=857.09,95%CI(746.07,968.11),P<0.001]的甲状旁腺激素(PTH)水平均显著降低;MWA后1天[WMD=0.39,95%CI(0.33,0.45),P<0.001;WMD=0.29,95%CI(0.16,0.41),P<0.001]和1周[WMD=0.23,95%CI(0.02,0.43),P<0.05;WMD=0.31,95%CI(0.02,0.61),P<0.05]钙和磷水平均下降。MWA后神经损伤发生率为1.20%[效应量(ES)=0.02,95%CI(-0.00,0.05),P>0.05],低钙血症发生率为21.69%[ES=0.60,95%CI(0.39,0.81),P<0.001],声音嘶哑发生率为5.62%[ES=0.06,95%CI(0.03,0.09),P<0.001],血肿发生率为1.61%[ES=0.03,95%CI(-0.01,0.06),P=0.095]。结论MWA治疗SHPT有效且安全。 Objective To systematically evaluate the efficacy and safety of microwave ablation(MWA)for treatment of secondary hyperparathyroidism(SHPT).Methods PubMed,Embase,Cochrane Library,CNKI and Wanfang Med Online were searched for relevant literatures published before December 31,2020.Then Stata 15.0 software was used for meta-analysis in evaluating the efficacy and safety of MWA for treatment of SHPT.Results According to the inclusion and exclusion criteria,a total of 249 patients from 9 articles were enrolled in this study.Compared with pre-ablation,the levels of parathyroid hormone(PTH)were significantly lower 1 day(weighted mean difference[WMD]=1142.04,95%CI[783.03,1501.06],P<0.001),1 week(WMD=859.85,95%CI[758.97,960.74],P<0.001),1 month(WMD=800.29,95%CI[687.12,913.47],P<0.001)and 6 months(WMD=857.09,95%CI[746.07,968.11],P<0.001)after MWA,while the levels of calcium and phosphorus were significantly lower 1 day(WMD=0.39,95%CI[0.33,0.45],P<0.001;WMD=0.29,95%CI[0.16,0.41],P<0.001)and 1 week(WMD=0.23,95%CI[0.02,0.43],P<0.05;WMD=0.31,95%CI[0.02,0.61],P<0.05)after MWA.The incidence of nerve injury was 1.20%(effect size[ES]=0.02,95%CI[-0.00,0.05],P>0.05)after MWA,of hypocalcemia was 21.69%(ES=0.60,95%CI[0.39,0.81],P<0.001),of voice hoarse was 5.62%(ES=0.06,95%CI[0.03,0.09],P<0.001),and of hematoma was 1.61%(ES=0.03,95%CI[-0.01,0.06],P=0.095).Conclusion MWA was effective and safe for treating SHPT.
作者 曹晓静 李妍 魏莹 赵朕龙 伍洁 彭丽丽 于明安 CAO Xiaojing;LI Yan;WEI Ying;ZHAO Zhenlong;WU Jie;PENG Lili;YU Ming'an(Department of Interventional Medicine, China-Japan Friendship Hospital,Beijing 100029, China)
出处 《中国介入影像与治疗学》 北大核心 2021年第10期577-582,共6页 Chinese Journal of Interventional Imaging and Therapy
基金 首都临床特色应用研究项目(Z181100001718135) 中日友好医院院级科研基金(2019-2-HL-4)。
关键词 甲状旁腺功能亢进症 继发性 超声检查 微波消融 荟萃分析 hyperparathyroidism,secondary ultrasonography microwave ablation meta-analysis
  • 相关文献

参考文献4

二级参考文献37

  • 1杨斌,傅宁华,刘萍,孟庆欣,李箬欣,段晓艳.彩色多普勒超声对继发甲状旁腺机能亢进超声引导无水酒精治疗的疗效评价[J].中国介入影像与治疗学,2006,3(1):49-51. 被引量:4
  • 2Sophie A Jamal,Ben Vandermeer,Paolo Raggi,David C Mendelssohn,Trish Chatterley,Marlene Dorgan,Charmaine E Lok,David Fitchett,Ross T Tsuyuki.Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis[J]. The Lancet . 2013 被引量:2
  • 3Garabed Eknoyan,Adeera Levin,Nathan W Levin.??Bone metabolism and disease in chronic kidney disease(J)American Journal of Kidney Diseases . 2003 被引量:2
  • 4Tadao Akizawa,Takashi Akiba,Hideki Hirakata,Eriko Kinugasa,Yoshihiro Tominaga,Masafumi Fukagawa,Keitaro Yokoyama,Wuyan Zhang,Peter G. Linde,Masashi Suzuki.??Comparison of P aricalcitol With M axacalcitol Injection in J apanese Hemodialysis Patients With Secondary Hyperparathyroidism(J)Ther Apher Dial . 2015 (3) 被引量:1
  • 5Salah Bashir,Hayder Omer,Mahmoud Aamer,Rashid Somialy,Mohamed Morsy.??Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients(J)Saudi Journal of Kidney Diseases and Transplantat . 2015 (6) 被引量:1
  • 6Tianzhao Han,Gong Rong,Dayong Quan,Ying Shu,Zhu Liang,Ninglan She,Manli Liu,Bing Yang,Gong Cheng,Yongman Lv,Leonard Stern,Sihe Wang.??Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease(J)BioMed Research International . 2012 被引量:1
  • 7Loupy, Alexandre,Ramakrishnan, Suresh Krishna,Wootla, Bharath,Chambrey, Régine,de la Faille, Renaud,Bourgeois, Soline,Bruneval, Patrick,Mandet, Chantal,Christensen, Erik Ilso,Faure, Hélène,Cheval, Lydie,Laghmani, Kamel,Collet, Corinne,Eladari, Dominique,Dodd, Robert H,Ruat, Martial,Houillier, Pascal.??PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor(J)EN . 2012 (9) 被引量:1
  • 8Halil Zeki Tonbul,Yalcin Solak,Huseyin Atalay,Kultigin Turkmen,Lutfullah Altintepe.??Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study(J)Renal Failure . 2012 (3) 被引量:1
  • 9Xianglei Kong,Luxia Zhang,Ling Zhang,Nan Chen,Yong Gu,Xueqing Yu,Wenhu Liu,Jianghua Chen,Liren Peng,Weijie Yuan,Hua Wu,Wei Chen,Minhua Fan,Liqun He,Feng Ding,Xiangmei Chen,Zuying Xiong,Jinyuan Zhang,Qiang Jia,Wei Shi,Changying Xing,Xi.Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrology . 2012 被引量:1
  • 10Palmer S.C.,Hayen A.,Macaskill P.,Craig J.C.,Strippoli G.F.M.,Pellegrini F.,Elder G.J.Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis. JAMA - Journal of the American Medical Association . 2011 被引量:2

共引文献47

同被引文献28

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部